Rationale, design, and baseline characteristics of the DANish randomized, controlled, multicenter study to assess the efficacy of Implantable cardioverter defibrillators in patients with non-ischemic Systolic Heart failure on mortality (DANISH)

American Heart Journal

Volumn 179, Issue , 2016, Pages 136-141

  Thune, Jens Jakob ^a   Pehrson, Steen ^a   Nielsen, Jens Cosedis ^b   Haarbo, Jens ^a   Videbæk, Lars ^c   Korup, Eva ^d   Jensen, Gunnar ^e   Hildebrandt, Per ^f   Steffensen, Flemming Hald ^g   Bruun, Niels Eske ^a,h   Eiskjær, Hans ^b   Brandes, Axel ^c   Thøgersen, Anna Margrethe ^d   Egstrup, Kenneth ^c   Hastrup Svendsen, Jesper ^a   Høfsten, Dan Eik ^a   Torp Pedersen, Christian ^d   Køber, Lars ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e ROSKILDE HOSPITAL   (Denmark)

^f Frederiksberg Heart Clinic   (Denmark)

^g LILLEBAELT HOSPITAL   (Denmark)

^h AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID ANTAGONIST;

ADULT; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART ARREST; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SUDDEN CARDIAC DEATH; SYSTOLIC HEART FAILURE; THERAPY EFFECT; TREATMENT OUTCOME; CLINICAL TRIAL; COMPLICATION; DEATH, SUDDEN, CARDIAC; HEART FAILURE, SYSTOLIC; HYPERTENSION; MIDDLE AGED; VALVULAR HEART DISEASE; VERY ELDERLY; YOUNG ADULT;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC RESYNCHRONIZATION THERAPY; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART FAILURE, SYSTOLIC; HEART VALVE DISEASES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MORTALITY; YOUNG ADULT;

EID: 84979282974     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2016.06.016     Document Type: Article

References (17)

1. 1. Cubbon, RM, Gale, CP, Kearney, LC, et al. Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction astudy across therapeutic eras. Circ Heart Fail 4 (2011), 396–403.
2. 2. Connolly, SJ, Hallstrom, AP, Cappato, R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J 21 (2000), 2071–2078.
3. 3. Moss, AJ, Hall, WJ, Cannom, DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 335 (1996), 1933–1940.
4. 4. Buxton, AE, Lee, KL, Fisher, JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 341 (1999), 1882–1890.
5. 5. Moss, AJ, Zareba, W, Hall, WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002), 877–883.
6. 6. Bardy, GH, Lee, KL, Mark, DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005), 225–237.
7. 7. Bänsch, D, Antz, M, Boczor, S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy the Cardiomyopathy trial (CAT). Circulation 105 (2002), 1453–1458.
8. 8. Strickberger, SA, Hummel, JD, Bartlett, TG, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia—AMIOVIRT. J Am Coll Cardiol 41 (2003), 1707–1712.
9. 9. Kadish, A, Quigg, R, Schaechter, I, et al. Defibrillators in nonischemic cardiomyopathy treatment evaluation. Pacing Clin Electrophysiol 23 (2000), 338–343.
10. 10. Bristow, MR, Saxon, LA, Boehmer, J, et al. Cardiacresynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 (2004), 2140–2150.
11. 11. Kirkfeldt, RE, Johansen, JB, Nohr, EA, et al. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J 35 (2014), 1186–1194.
12. 12. Moss, AJ, Schuger, C, Beck, CA, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 367 (2012), 2275–2283.
13. 13. Yancy, CW, Jessup, M, Bozkurt, B, et al. 2013 ACCF/AHA guideline for the management of heart failure areport of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128 (2013), e240–e327.
14. 14. McMurray, JJV, Adamopoulos, S, Anker, SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33 (2012), 1787–1847.
15. 15. Lam, SKH, Owen, A, Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ, 335, 2007, 925.
16. 16. Colquitt, JL, Mendes, D, Clegg, AJ, et al. Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation. Health Technol Assess 18 (2014), 1–560.
17. 17. McCrohon, JA, Moon, JCC, Prasad, SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 108 (2003), 54–59.